North America Herpes Simplex Virus Treatment Market Size & Outlook
North America herpes simplex virus treatment market, 2018-2030 (US$M)
Related Markets
North America herpes simplex virus treatment market highlights
- The North America herpes simplex virus treatment market generated a revenue of USD 3,194.4 million in 2023.
- The market is expected to grow at a CAGR of 3.2% from 2024 to 2030.
- In terms of segment, route of administration was the largest revenue generating therapeutics in 2023.
- Type is the most lucrative therapeutics segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 3,194.4 million |
| Market revenue in 2030 | USD 3,985.1 million |
| Growth rate | 3.2% (CAGR from 2023 to 2030) |
| Largest segment | Route of administration |
| Fastest growing segment | Type |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Type, Drug, Distribution Channel, Route of Administration |
| Key market players worldwide | GSK PLC, Viatris Inc, Fresenius SE & Co KGaA, Teva Pharmaceutical Industries Ltd, Sanofi SA, Novartis AG ADR, Glenmark Pharmaceuticals, Emcure Pharmaceuticals, Carlsbad Technology, Apotex Inc. |
Other key industry trends
- In terms of revenue, North America region accounted for 32.3% of the global herpes simplex virus treatment market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- MEA is the fastest growing regional market and is projected to reach USD 1,876.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Herpes Simplex Virus Treatment Market Scope
Herpes Simplex Virus Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America herpes simplex virus treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to herpes simplex virus treatment market will help companies and investors design strategic landscapes.
Route of administration was the largest segment with a revenue share of 25% in 2024. Horizon Databook has segmented the North America herpes simplex virus treatment market based on type, drug, distribution channel, route of administration covering the revenue growth of each sub-segment from 2018 to 2030.
- North America Herpes Simplex Virus Treatment Type Outlook (Revenue, USD Million, 2018-2030)
- Herpes Simplex Virus 1
- Herpes Simplex Virus 2
- North America Herpes Simplex Virus Treatment Drug Outlook (Revenue, USD Million, 2018-2030)
- Acyclovir
- Valacyclovir
- Famciclovir
- Other Drug
- North America Herpes Simplex Virus Treatment Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America Herpes Simplex Virus Treatment Route of Administration Outlook (Revenue, USD Million, 2018-2030)
- Oral
- Injectable
- Topical
Reasons to subscribe to North America herpes simplex virus treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America herpes simplex virus treatment market databook
-
Our clientele includes a mix of herpes simplex virus treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America herpes simplex virus treatment market , including forecasts for subscribers. This continent databook contains high-level insights into North America herpes simplex virus treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America herpes simplex virus treatment size, by country, 2018-2030 (US$M)
North America Herpes Simplex Virus Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
